Who is sponsoring NCT00804219?

NCT00804219 is sponsored by Medical University of Vienna.

What condition does NCT00804219 study?

NCT00804219 studies Tick-borne Encephalitis.

What drugs are being tested in NCT00804219?

Interventions: TBE vaccination and influenza vaccination.

What is the status of NCT00804219?

NCT00804219 is currently COMPLETED.

Last reviewed 2011-07-20 · How we verify

Characterization of Humoral and Cellular Immunity of Low and High-responders After TBE Vaccination

NCT00804219 Phase 4 COMPLETED

The phenomenon of no- and low-responsiveness has been described after applications of different vaccines (e.g. hepatitis B, TBE) and is concerning about 2-10% of the vaccinees. The aim of this project is to investigate the humoral and cellular immune responses of low-responders after TBE vaccination in order to find parameters regarding immunoregulation against TBE. It is of interest if non-responsiveness is a general immunological deficit of a distinct patient group or if it is a antigen-specific phenomenon.

Details

Lead sponsor	Medical University of Vienna
Phase	Phase 4
Status	COMPLETED
Enrolment	67
Start date	2008-12
Completion	2010-11

Conditions

Tick-borne Encephalitis

Interventions

TBE vaccination and influenza vaccination

Primary outcomes

cellular TBE immunity (cytokine production) 7 days after TBE-booster plus influenza vaccination — 7 days after TBE-booster plus influenza vaccination

Countries

Austria